GammaCan to work on VitiGam

Advanced stage melanoma represents a large unmet medical need as there currently are no safe and effective therapies available to patients, the companies said.

By JERUSALEM POST STAFF
August 23, 2006 08:34

GammaCan International and Life Therapeutics on Tuesday signed a term sheet to collaborate to jointly develop VitiGam, an innovative, anti-cancer product designed to target metastatic malignant melanoma patients with Stage III and IV disease. Advanced stage melanoma represents a large unmet medical need as there currently are no safe and effective therapies available to patients, the companies said. The partners will share the costs and expenses relating to the development, supply, collection, manufacture, storage and commercialization of VitiGam, as well as their respective portion in any proceeds resulting of the collaboration. Life Therapeutics will also supply plasma to GammaCan for the project.


Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS

Israel Weather
  • 13 - 22
    Beer Sheva
    16 - 21
    Tel Aviv - Yafo
  • 12 - 19
    Jerusalem
    15 - 23
    Haifa
  • 18 - 28
    Elat
    16 - 29
    Tiberias